Fidelity Investments
PSTV

Fidelity Investments’s Plus Therapeutics PSTV Stock Holding History

Fidelity Investments’s Portfolio PSTV Stock Details PSTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-5
Closed -$580 – 5555
2023
Q1 		$580 Buy
+5
New +$673 ﹤0.01% 4782
2020
Q4 		– Hold
0
– – – 4197
2020
Q3 		– Hold
0
– – – 3929
2020
Q2 		– Hold
0
– – – 4054

Other funds holding PSTV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Fidelity Investments's PSTV Position: Q2 2023 in Review

Fidelity Investments sold out of Plus Therapeutics (PSTV) in Q2 2023, closing a stake of 5 shares — an estimated $580 sold.

Fidelity Investments first reported a position in PSTV in Q1 2023 and held it in 1 quarter. The position peaked at $580 in Q1 2023. 6 funds tracked by Wall St. Rank hold PSTV as of Q2 2023.

  • Fidelity Investments reported no remaining Plus Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Fidelity Investments sold 5 Plus Therapeutics shares in Q2 2023, an estimated $580.
  • Fidelity Investments first reported a position in Plus Therapeutics in Q1 2023 and held it in 1 quarter.
  • Fidelity Investments's Plus Therapeutics position peaked at $580 in Q1 2023.
  • 6 funds tracked by Wall St. Rank held Plus Therapeutics as of Q2 2023.

Based on Fidelity Investments's 13F filing for Q2 2023, filed 11 Aug 2023.